Edible plant exosome-like nanovectors for vaccination
Provided are compositions and methods for using the same. In some embodiments, the compositions include an EPELN encapsulating and/or having associated therewith an active agent and a plasma membrane derived from a tumor and/or cancer cell coating the EPELN. In some embodiments, the active agent is a therapeutic agent or an immune response modifier, and in some embodiments the plasma membrane has one or more tumor-associated and/or cancer-associated antigens. Also provided are methods for using the compositions for treating tumors and/or cancers, inducing anti-tumor and/or anti-cancer immune responses, activating antigen-presenting cells, targeting CD11c dendritic cells, and preventing or reducing metastasis.
1 . A composition comprising:
an edible-plant derived exosome-like nanoparticle (EPELN) comprising a lipid bilayer encapsulating and/or having associated therewith an immune response modifier; wherein the immune response modifier comprises an miRNA selected from the group consisting of miR18a (5′-UAAGGUGCAUCUAGUGCAGAUAG-3′; SEQ ID NO: 1) and miR17 (5′-CAAAGUGCUUACAGUGCAGGUAG-3′; SEQ ID NO: 2); and
a plasma membrane; wherein the plasma membrane is derived from a tumor and/or cancer cell and wherein the plasma membrane consists of one or more tumor-associated antigens and/or cancer associated antigens.
2 . The composition of claim 1 , wherein the edible plant is a mushroom.
3 . The composition of claim 1 , wherein the (EPELN) further encapsulates and/or has associated therewith a therapeutic agent.
4 . The composition of claim 3 , wherein the therapeutic agent is selected from a phytochemical agent, an immune response inducing and/or enhancing agent, and a chemotherapeutic agent.
5 . The composition of claim 3 , wherein the therapeutic agent is a phytochemical agent, optionally wherein the phytochemical agent is selected from curcumin, resveratrol, baicalein, equal, fisetin, and quercetin.
6 . The composition of claim 3 , wherein the therapeutic agent is a chemotherapeutic agent, optionally wherein the chemotherapeutic agent is selected from the group consisting of retinoic acid, 5-fluorouracil, vincristine, actinomycin D, adriamycin, cisplatin, docetaxel, doxorubicin, and taxol.
7 . The composition of claim 3 , wherein the therapeutic agent comprises a nucleic acid molecule selected from the group consisting of an siRNA, a microRNA, and a mammalian expression vector.
8 . A pharmaceutical composition comprising a pharmaceutically-acceptable vehicle, carrier, and/or excipient and the composition of claim 1 , optionally wherein the pharmaceutical composition is pharmaceutically acceptable for use in a human.
9 . A method for treating a tumor and/or a cancer, the method comprising administering to a subject in need thereof an effective amount of a composition, the composition comprising:
(i) an edible-plant derived exosome-like nanoparticle (EPELN) comprising a lipid bilayer encapsulating and/or having associated therewith an immune response modifier; wherein the immune modifier comprises an miRNA selected from the group consisting of miR18a (5′-UAAGGUGCAUCUAGUGCAGAUAG-3′; SEQ ID NO: 1) and miR17 (5′-CAAAGUGCUUACAGUGCAGGUAG-3′; SEQ ID NO: 2); and
(ii) a plasma membrane derived from a tumor and/or cancer cell coating the EPELN; and wherein the plasma membrane consists of one or more tumor-associated antigens and/or cancer associated antigens.
10 . The method of claim 9 , wherein the tumor cell and/or cancer cell is autologous to the subject.
11 . A method for inducing an anti-tumor and/or an anti-cancer immune response in a subject, the method comprising administering to the subject an effective amount of the composition of claim 1 , whereby an anti-tumor and/or anti-cancer immune response is induced in the subject to at least one tumor-associated and/or cancer-associated antigen present in the composition.
12 . A method for activating antigen-presenting cells (APCs) in a subject, the method comprising administering to the subject an effective amount of the composition of claim 1 , whereby APCs present in the subject are activated against at least one tumor-associated and/or cancer associated antigen present in the subject.
13 . A method for targeting a CD11c dendritic cell present in or isolated from a subject, the method comprising contacting the CD11c dendritic cell with a composition of claim 1 .
14 . A method for inhibiting or reducing metastasis of a cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition of claim 1 .
15 . The method of claim 9 , wherein the composition is administered orally or intravenously.
16 . The method of claim 9 , wherein administering the composition induces an immune response in the subject to at least one tumor-associated and/or cancer-associated antigen present in the composition.
17 . The method of claim 9 , wherein the EPELN is derived from a mushroom.
18 . The method of claim 9 , wherein the immune response modifier comprises miR 18a (5′UAAGGUGCAUCUAGUGCAGAUAG-3′; SEQ ID NO: 1).
19 . The method of claim 9 , wherein the (EPELN) further encapsulates and/or has associated therewith a therapeutic agent.
20 . The method of claim 19 , wherein the therapeutic agent is selected from a phytochemical agent and a chemotherapeutic agent, optionally wherein the therapeutic agent comprises:
(i) a phytochemical agent selected from curcumin, resveratrol, baicalein, equal, fisetin, and quercetin; or
(ii) a chemotherapeutic agent selected from the group consisting of retinoic acid, 5-fluorouracil, vincristine, actinomycin D, adriamycin, cisplatin, docetaxel, doxorubicin, and taxol: or
(iii) a nucleic acid molecule selected from an siRNA a microRNA and a mammalian expression vector.
21 . The composition of claim 1 , wherein the wherein the immune response modifier comprises miR17 (5′-CAAAGUGCUUACAGUGCAGGUAG-3′; SEQ ID NO: 2).
22 . The composition of claim 9 , wherein the wherein the immune response modifier comprises miR17 (5′-CAAAGUGCUUACAGUGCAGGUAG-3′; SEQ ID NO: 2).